Core Insights - Labcorp Holdings reported fourth-quarter 2025 adjusted earnings per share (EPS) of $4.07, beating the Zacks Consensus Estimate by 3% and reflecting an 18% increase from the previous year [1][9] - Full-year adjusted EPS was $16.44, representing a year-over-year growth of 12.8% and exceeding the Zacks Consensus Estimate by 0.8% [2] Revenue Performance - Fourth-quarter revenues increased by 5.7% year over year to $3.52 billion, although this figure missed the Zacks Consensus Estimate by 1% [3] - Full-year revenues rose 7.2% year over year to $13.95 billion, also missing the Zacks Consensus Estimate by 0.3% [3] Segment Analysis - Diagnostics Laboratories segment reported revenues of $2.73 billion for the fourth quarter, reflecting a 5.5% improvement year over year [5] - Biopharma Laboratory Services revenues increased by 3.4% to $793 million, driven by organic growth of 0.6% and a foreign currency translation gain of 2.8% [6] Margin Performance - Gross margin expanded by 133 basis points to 28.2% in the fourth quarter, despite a 3.7% rise in the cost of revenues [7] - Adjusted operating income improved by 51% year over year to $454.6 million, with the adjusted operating margin expanding by 389 basis points to 12.9% due to a 9.5% decline in SG&A expenses [7] Cash Position - Labcorp ended the fourth quarter with cash and cash equivalents of $532.3 million, down from $1.52 billion at the end of the fourth quarter of 2024 [10] - Long-term debt remained stable at $5.08 billion, while cumulative net cash provided by operating activities was $1.64 billion, slightly up from $1.59 billion a year ago [10] 2026 Guidance - Labcorp expects 2026 revenues to be in the range of $14.61 billion to $14.79 billion, indicating growth of 4.7% to 6% [12] - Adjusted EPS for 2026 is projected to be between $17.55 and $18.25, with the Zacks Consensus Estimate at $17.62 [12] Strategic Developments - In 2025, Labcorp expanded partnerships with health systems and regional/local laboratories, closing 13 transactions [14] - The company launched over 130 innovative new tests in various fields and announced a strategic investment to build a new 500,000 square foot Central Laboratory facility [14]

Core Insights - Ondas Inc. (ONDS) is advancing its autonomous defense technologies through a significant contract with a NATO-country customer for its Iron Drone Raider counter-UAS system, following successful deployment at an international airport, validating its technology in real-world scenarios [1][4] Group 1: Product and Technology - The Iron Drone Raider employs a net-based kinetic interception system, effectively neutralizing hostile drones with minimal operational disruption, making it suitable for high-value environments like airports [2] - Ondas is developing a comprehensive low-altitude airspace defense architecture that integrates cyber-over-RF mitigation and AI-based detection, aiming to provide a complete solution rather than a standalone product [3] Group 2: Market Position and Financial Outlook - The recent contract enhances Ondas' backlog and revenue visibility, supporting its expansion in the civil counter-UAS market, which is characterized by high barriers to entry [4] - Ondas' stock has seen a decline of 23.5% over the past month, contrasting with a 20.7% growth in the Zacks Wireless-National industry [7] - The company's valuation appears high, with a forward Price/Sales ratio of 19.73 compared to the industry average of 1.99, indicating potential overvaluation [8]

Core Viewpoint - Novocure (NVCR) has received FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, ahead of the expected timeline of Q2 2026 [1][2] Company Developments - The FDA approval is based on the successful phase III study, PANOVA-3, which showed that Optune Pax combined with gem/nab-pac significantly improved overall survival compared to gem/nab-pac alone [2][9] - Novocure has other commercialized therapies using Tumor Treating Fields (TTFields), including Optune Gio for glioblastoma multiforme and Optune Lua for metastatic non-small cell lung cancer [3] - The company is also developing therapies for treating metastatic pancreatic cancer and newly diagnosed glioblastoma multiforme [3] Clinical Data - The PANOVA-3 study demonstrated a median overall survival (mOS) of 16.2 months for patients treated with Optune Pax and gem/nab-pac, compared to 14.2 months for those receiving gem/nab-pac alone [8][10] - The one-year survival rate was 68.1% for the Optune Pax group versus 60.2% for the gem/nab-pac group [10] - Additionally, the median time to pain progression improved to 15.2 months with Optune Pax compared to 9.1 months for gem/nab-pac alone [10] Market Potential - The pancreatic cancer market is projected to grow from $3.01 billion to $9.57 billion between 2025 and 2034, at a CAGR of 13.7%, driven by increasing cases and advancements in treatment options [12] - The approval of Optune Pax is expected to enhance Novocure's market prospects, given the limited treatment options currently available for pancreatic cancer [12] Financial Performance - Novocure reported preliminary net revenues of $174.4 million for Q4 and full-year 2025, reflecting an 8% year-over-year increase, with total revenues for the year reaching $655 million [13]

Core Insights - Celestica Inc. (CLS) is a significant player in the global defense industry, focusing on high-reliability electronic systems for military applications [1] - The company provides a range of defense solutions, including rugged avionics, secure communication systems, and radar electronics for various platforms [2] - Celestica supports defense customers throughout the entire product lifecycle, adhering to strict regulatory standards [3] - With rising global defense spending, Celestica is positioned to benefit from increased demand for advanced military electronics [4] Company Overview - Celestica designs and manufactures high-reliability electronics for global defense original equipment manufacturers (OEMs) [8] - The company supplies components built for harsh conditions, including rugged avionics and UAV components [8] Competitive Landscape - Celestica faces competition from Jabil, Inc. and Sanmina Corporation, both of which provide electronics services for defense and aerospace systems [5][6] Financial Performance - Celestica's shares have increased by 112.2% over the past year, outperforming the industry growth of 71.5% [7] - The company trades at a forward price-to-earnings ratio of 30.09, higher than the industry average of 22.97 [9] - Earnings estimates for 2026 have risen by 7.55% to $8.83, while estimates for 2027 have increased by 7.05% to $12.61 [10] Earnings Estimates - The consensus estimate trend shows a positive revision of earnings estimates over the past 60 days, with significant increases for both 2026 and 2027 [11]

Core Insights - MongoDB's expanding partner network is becoming a structural growth lever, integrating the platform into the modern enterprise software stack and positioning Atlas as a default data layer [1] - The acquisition of Voyage AI enhances upsell opportunities, allowing AI-native customers to transition smoothly from Voyage embeddings to Atlas Vector Search and the core operational database [2] - Atlas revenues increased by 30% year over year, representing 75% of total revenues, with a net ARR expansion rate of 120%, indicating sustainable growth driven by partner adoption [3] Partner Ecosystem - The Zacks Consensus Estimate for fiscal 2026 projects total customers at 64,200, a 17.8% increase year over year, and customers generating over $100,000 in ARR at 2,786, a 16.3% increase year over year, suggesting an expanding partner ecosystem [4] - Co-sell agreements and broader integrations are expected to enhance MongoDB's growth trajectory, functioning as a long-term growth engine [4] Competitive Landscape - MongoDB faces significant competition from Snowflake and Amazon, both of which have extensive partner ecosystems [5] - Snowflake focuses on analytics workloads, while Amazon emphasizes vertically integrated services through AWS, but MongoDB differentiates itself by embedding directly into developer tools [6] Financial Performance - MongoDB shares have returned 62.2% over the past six months, outperforming the Zacks Internet – Software industry's decline of 22.4% and the Zacks Computer and Technology sector's return of 7.8% [7] - The stock is currently trading at a forward 12-month Price/Sales ratio of 10.36X, significantly higher than the industry's 3.9X, indicating a premium valuation [10] - The Zacks Consensus Estimate for fourth-quarter fiscal 2026 earnings is $1.47 per share, reflecting a year-over-year growth of 14.84% [12]

Core Insights - DTE Energy Company (DTE) reported fourth-quarter 2025 operating earnings per share (EPS) of $1.65, exceeding the Zacks Consensus Estimate of $1.52 by 8.6%, and reflecting a 9.3% increase from the previous year's figure of $1.51 [1] - The company reported GAAP earnings of $1.77 per share compared to $1.41 in the prior-year quarter [1] - For the full year 2025, DTE reported operating earnings of $7.36 per share, up from $6.83 in the previous year [1] Financial Performance - Operating net income for the quarter was $343 million, an increase from $314 million in the year-ago period [2] - DTE Electric invested over $3.6 billion to enhance reliability and develop cleaner energy generation [2] - DTE Gas allocated $661 million for upgrades to its natural gas system [2] Business Developments - During the quarter, DTE negotiated its first hyperscale data center contracts to provide 1.4 gigawatts (GW) of load for Oracle's new data center in Saline Township, MI, which is expected to deliver significant affordability benefits to customers [3] Segment Performance - DTE Electric reported earnings of $1.01 per share, up from 95 cents in the prior-year quarter [4] - DTE Gas reported operating earnings of 58 cents per share, compared to 50 cents in the year-ago period [4] - Non-Utility Operations reported operating earnings of 40 cents per share, down from 56 cents in the fourth quarter of 2024 [4] Future Guidance - DTE Energy provided its 2026 operating EPS guidance, expecting it to be in the range of $7.59-$7.73, with the Zacks Consensus Estimate for earnings at $7.72, near the higher end of the company's guidance [5] Market Position - DTE Energy currently holds a Zacks Rank 3 (Hold) [6]

Core Insights - Bristol Myers Squibb's (BMY) revenue performance in 2025 shows a transition with growth from new products offsetting declines in legacy drugs [1][9] - Total revenues were flat year over year, with a 17% increase in sales from the growth portfolio and a 15% decline in legacy products due to generic competition [1][9] Legacy and Growth Portfolio - The legacy portfolio, including drugs like Eliquis, Revlimid, Pomalyst, Sprycel, and Abraxane, is under pressure due to loss of exclusivity for four drugs [2] - The growth portfolio, featuring drugs such as Opdivo, Opdivo Qvantig, Orencia, and others, is crucial for maintaining revenue stability [2] Immuno-Oncology and Key Drug Performance - The immuno-oncology (IO) portfolio, particularly Opdivo, continues to show strong sales momentum due to label expansions and market share growth [3] - Opdivo Qvantig's approval has contributed to growth, with robust initial uptake across approved tumor types in the U.S. [4] - Reblozyl has achieved an annualized sales run rate above $2 billion, while Breyanzi has surpassed $1 billion in annualized sales [5] Future Outlook and Competition - Management anticipates a further decline of 12-16% in legacy sales for 2026, guiding revenues to $46.0-$47.5 billion [7] - BMY faces increasing competition in oncology from companies like Merck, particularly with the success of Keytruda [8][10] Market Performance and Valuation - BMY's shares have gained 12.7% over the past year, compared to the industry's growth of 19.6% [13] - The company is trading at a price/earnings ratio of 9.80x forward earnings, which is lower than the large-cap pharma industry's average of 18.82x [14] Earnings Estimates - The Zacks Consensus Estimate for 2026 EPS has increased to $6.15 from $6.04, while the estimate for 2027 has risen to $5.94 [17]

Core Insights - Amkor Technology (AMKR) shares have experienced a significant decline of 16.8% from their 52-week high, despite a remarkable 97.4% increase over the past six months, outperforming the broader technology sector [1][8] - The company's strong performance is attributed to rising demand for advanced packaging solutions, particularly in AI and high-performance computing, with a focus on the High Density Fan Out (HDFO) platform [2][9] Financial Performance - In Q4, AMKR reported net sales of $1.89 billion, a 16% year-over-year increase, exceeding Zacks Consensus Estimate by 3.35%. EPS reached 69 cents, surpassing expectations by 60.5% [5] - For 2025, AMKR's sales were $6.71 billion, reflecting a 6% year-over-year growth, driven by advancements in computing and automotive sectors [5] Future Projections - For the fiscal first quarter, AMKR anticipates sales between $1.6 billion and $1.7 billion, indicating a potential 25% year-over-year growth at the midpoint. Gross margin is expected to normalize between 12.5% and 13.5% [6] - The company plans to invest $2.5 billion to $3 billion in capital expenditures in 2026, primarily for the Arizona facility and HDFO capacity expansion in Korea [6][9] Competitive Landscape - AMKR faces stiff competition from ASE Technology, which has a larger scale and customer base, as well as from Taiwan Semiconductor and Intel, which are enhancing their own packaging capabilities [11] - The competitive pressure is compounded by AMKR's ambitious capacity expansion plans, which may increase execution risks [11][12] Valuation Concerns - AMKR's forward price-to-earnings ratio stands at 28.15x, above the sector median of 25.17x, raising concerns about valuation as the company enters a capital-intensive phase [12] - The normalization of margins and reliance on timely capacity buildouts and customer program ramps contribute to the perception of a stretched valuation [12] Conclusion - AMKR is positioned for growth in advanced packaging, supported by strong Q4 results and investments in AI-driven computing programs. However, the company must navigate increasing competition and execution risks as it scales its operations [14]

Group 1: TTM Technologies, Inc. (TTMI) - TTM Technologies manufactures and sells printed circuit boards and has a Zacks Rank 1 [1] - The Zacks Consensus Estimate for TTM's current year earnings increased by 12.9% over the last 60 days [1] - TTM's shares gained 42.6% over the last three months, outperforming the S&P 500's advance of 2.3% [1] - The company possesses a Momentum Score of A [1] Group 2: Advanced Energy Industries, Inc. (AEIS) - Advanced Energy Industries supplies precision power conversion, measurement, and control solutions for semiconductor manufacturing and has a Zacks Rank 1 [2] - The Zacks Consensus Estimate for Advanced Energy's current year earnings increased by 9.5% over the last 60 days [2] - Advanced Energy's shares gained 58.3% over the last three months, significantly outperforming the S&P 500's advance of 2.3% [2] - The company possesses a Momentum Score of A [2] Group 3: Cameco Corporation (CCJ) - Cameco Corporation produces uranium fuel and provides nuclear energy solutions globally and has a Zacks Rank 1 [3] - The Zacks Consensus Estimate for Cameco's current year earnings increased by 5.4% over the last 60 days [3] - Cameco's shares gained 36% over the last three months, again outperforming the S&P 500's advance of 2.3% [3] - The company possesses a Momentum Score of A [3]

Core Insights - Itron reported a revenue of $571.66 million for the quarter ended December 2025, reflecting a year-over-year decline of 6.7% while EPS increased to $2.46 from $1.35 in the same quarter last year, exceeding the Zacks Consensus Estimate for EPS by 12.55% [1] Revenue Performance - Revenue from Outcomes was $111.83 million, surpassing the four-analyst average estimate of $98.38 million, with a year-over-year increase of 22.6% [4] - Revenue from Device Solutions was $104.83 million, slightly above the average estimate of $95.82 million, but showed a year-over-year decline of 3.4% [4] - Revenue from Networked Solutions was $351.95 million, below the estimated $366.53 million, representing a year-over-year decrease of 14.8% [4] - Service revenues from Networked Solutions reached $29.09 million, exceeding the average estimate of $24.5 million, with a year-over-year increase of 13.1% [4] - Product revenues from Device Solutions were $104.18 million, above the average estimate of $96.46 million, but down 3% year over year [4] - Product revenues from Networked Solutions were $322.86 million, below the estimated $339.58 million, reflecting a year-over-year decline of 16.7% [4] - Total product revenues were $474.33 million, slightly below the average estimate of $480.12 million, with a year-over-year decrease of 10.9% [4] - Service revenues from Outcomes were $64.54 million, exceeding the average estimate of $60.15 million, with a year-over-year increase of 20.5% [4] - Service revenues from Device Solutions were $0.65 million, below the estimated $1.09 million, showing a significant year-over-year decline of 43.9% [4] - Total service revenues were $97.33 million, surpassing the average estimate of $85.75 million, with a year-over-year increase of 21% [4] - Product revenues from Outcomes were $47.29 million, exceeding the average estimate of $38.97 million, with a year-over-year increase of 25.8% [4] Stock Performance - Itron's shares have returned -10.7% over the past month, compared to a -1.4% change in the Zacks S&P 500 composite, indicating potential underperformance in the near term with a Zacks Rank of 4 (Sell) [3]